SC
TVTX icon

Stephens Consulting’s Travere Therapeutics TVTX Stock Holding History

Stephens Consulting’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$359 – 1956
2025
Q1 		$359 Buy
+20
New +$406 ﹤0.01% 1279
2024
Q3 		– Sell
-115
Closed -$946 – 647
2024
Q2 		$946 Buy
+115
New +$775 ﹤0.01% 601

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's TVTX Position: Q2 2025 in Review

Stephens Consulting sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 20 shares — an estimated $359 sold.

Stephens Consulting first reported a position in TVTX in Q2 2024 and held it in 2 quarters. The position peaked at $946 in Q2 2024. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Stephens Consulting reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 20 Travere Therapeutics shares in Q2 2025, an estimated $359.
  • Stephens Consulting first reported a position in Travere Therapeutics in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Travere Therapeutics position peaked at $946 in Q2 2024.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.